Air Global PLC Q3 FY2026 earnings call

• Core Business Resilience: Air Global remains the global leader in flavoured shisha molasses with an estimated 36-44% global volume share. Shisha volumes have remained resilient despite broader tobacco declines, supported by strong consumer demand and affordable pricing.
• Strategic Pivot to Vaping: The company is prioritizing its US rechargeable pod vape platform, CrownSwitch, over nicotine pouches due to better near-term profitability trends and a crackdown on illicit vapes. A PMTA submission for CrownSwitch was filed in early November.
• Supply Chain Recovery: Following the closure of the Strait of Hormuz, alternative routes were established. Shipment activity has recovered, though end-consumer demand remains resilient.
• Cost Pressures: Elevated logistics, energy, shipping, and raw material costs linked to Middle East conflicts are compressing margins. The Romania facility is on track to open in Q1 2027 to diversify manufacturing.
• Capital Structure: Issued $425 million senior unsecured notes maturing in 2031 to refinance existing debt. Established a $100 million share repurchase program through December 2029.
• GreenTank Investment: Maintains a warrant option for GreenTech’s quantum chip technology, which powers CrownSwitch. Decision to exercise the warrant depends on FDA acceptance of the PMTA submission.

America: Q3 revenue increased 25.6% to $22 million; adjusted EBITDA declined 3.6% to $8 million due to higher cost of goods sold. For the first nine months, revenue grew 10% and adjusted EBITDA increased 10.5%. MIA (Middle East, Africa, Asia): Q3 revenue rose 9.4% to $64 million; adjusted EBITDA increased 2.4% to $25 million. For the first nine months, revenue grew 5.7%, while adjusted EBITDA declined 2.2% due to corporate headquarters costs and supply chain pressures. Europe: Q3 revenue increased 4.9% to $14 million; adjusted EBITDA was $1 million (vs. breakeven prior year). For the first nine months, revenue grew 2.1%, while adjusted EBITDA declined to $1 million from $2 million. New Growth Categories: Q3 revenue was slightly negative due to trade incentive timing; adjusted EBITDA loss narrowed to $3 million from $4 million. For the first nine months, the loss narrowed to $11 million from $13 million.

• Full Year 2026 Revenue: Reiterating guidance for 4-6% growth in US dollars.
• Full Year 2026 Adjusted EBITDA: Reiterating guidance for low to mid single-digit growth.
• Full Year 2026 Volumes: Expecting broadly stable shipment volumes compared to 2025 (previously expected modest decline).
• Leverage Ratio: Revised upward; now expects year-end net debt to adjusted EBITDA of approximately 2.5 times (previously 2.1 times), driven by bond issuance and working capital timing.
• Capital Expenditure: Revised downward; expects full-year capex of $11 million to $14 million (previously $15 million to $18 million).
• Medium Term Framework: Unchanged. Low single-digit organic FSM volume growth, mid single-digit FSM revenue growth, and high single-digit FSM adjusted EBITDA growth.
• Net Debt Target: Expects net debt to adjusted EBITDA to decline to two times or below by December 2027.

• Geopolitical and Supply Chain Disruption: Ongoing conflict in the Middle East and the closure of the Strait of Hormuz have led to prolonged higher costs for shipping, insurance, security, and raw materials. This is expected to cause modest margin compression in 2026.
• Regulatory Risk: Success of the new CrownSwitch vape platform depends entirely on FDA approval of the PMTA submission. Failure or significant delay could hinder growth strategy.
• Illicit Trade: In European markets, particularly with rising excise taxes (e.g., Germany), there is a risk that illicit trade could undermine the legal market if authorities do not enforce regulations effectively.
• Margin Compression: Continued elevated logistics and factory footprint costs are weighing on gross and adjusted EBITDA margins until normalization occurs.
• Working Capital Volatility: Temporary working capital impacts from supply chain disruptions may affect cash flow and leverage ratios in the short term.

Q: Nick Anderson asked about volume recovery drivers (distributor replenishment vs. consumer demand) and channel inventory levels by region. / A: CEO Stuart Brazier stated Q3 recovered half of H1 volume lags, expecting flat full-year volumes. Inventory is higher at factories due to multiple sourcing routes for raw materials and building stocks at the new Poland facility. End-consumer demand remains resilient, and distributor inventories are normalizing with little excess or deficit by year-end.

Q: Moreo Adesina asked for the bridge of leverage increase (bond costs vs. working capital) and when cost pressures normalize. / A: CFO Bassem Lotfy and IR Head Gaurav Jain explained one-third of leverage increase is from refinancing costs, two-thirds from higher working capital due to prolonged disruption. Costs will normalize over time, allowing margin recovery. Pricing actions will continue to pass inflation to consumers.

Q: Gerald Pasquarelli asked about ideal conditions for US vape rollout and why vapes are prioritized over pouches. / A: CEO Stuart Brazier noted the FDA is cracking down on illicit vapes, expanding flavor options, and competitors show strong profitability. Pouches face intense competition and margin squeeze. Vapes offer a differentiated, profitable opportunity once PMTA is accepted.

Q: Kato Mukuru asked about share repurchase limits per year and potential gross margin expansion post-normalization. / A: CEO Stuart Brazier clarified no fixed annual limit; repurchases depend on trading volume (up to 20% of 30-day VWAP). He projected ~300 bps gross margin improvement over time as costs normalize. IR added this is a medium-term view, with further operating leverage possible.